Showing results (41-50 of 205) with videos related to
Sort By:
Pageof 21
Psychopharmacology. Supplementum|January 1, 1985
GABA dysfunction in the pathophysiology of tardive dyskinesiaC A Tamminga, G K Thaker, T N ChaseBiological Psychiatry|January 1, 1989
Increased saccadic distractibility in tardive dyskinesia: functional evidence for subcortical GABA dysfunctionG K Thaker, J A Nguyen, C A TammingaArchives of Neurology|April 1, 1985
Cholecystokinin and neurotensin gradients in human CSFC A Tamminga, P A LeWitt, T N ChaseNeuroreport|December 15, 1995
D2-family receptor distribution in human postmortem tissue: an autoradiographic studyR A Lahti, R C Roberts, C A TammingaBiological Psychiatry|August 1, 1990
Sleep polygraphy in schizophrenia: methodological issuesG K Thaker, A M Wagman, C A TammingaThe American Journal of Psychiatry|September 1, 1997
Time to clozapine response in a standardized trialR R Conley, W T Carpenter, C A TammingaInternational Clinical Psychopharmacology|August 5, 1998
The role of negative symptoms and cognitive dysfunction in schizophrenia outcomeC A Tamminga, R W Buchanan, J M GoldNeuroscience Research|April 4, 1998
Neurochemical and metabolic consequences of elevated cerebrospinal fluid quinolinic acid concentrations in rat brainK Maeda, H Kaneda, W O Whetsell, et al.Neuroscience Letters|March 15, 1985
Products of cholecystokinin (CCK)-octapeptide proteolysis interact with central CCK receptorsL Steardo, M Knight, C A Tamminga, et al.Synapse (New York, N.Y.)|February 17, 2001
Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathwaysK Sakai, X M Gao, T Hashimoto, et al.Pageof 21